
Biosimilars drive Sandoz growth ahead of unclear tariff effects in 2025
Sandoz reported a 9% growth in net sales of generics and biosimilars to third parties for 2024, marking a strong first financial year as an independent company. After completing its spin-off from Novartis in October 2023, Sandoz has been busy launching new …